ArticleHaematologica2022

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.

Anna Dodero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.